113558-15-9Relevant articles and documents
Regio-selective deglycosylation of icariin by cell suspension cultures of Glycyrrhiza uralensis and Morus alba
Zhang, De-Wu,Tao, Xiao-Yu,Chen, Ri-Dao,Yu, Li-Yan,Dai, Jun-Gui
, p. 656 - 661 (2015)
Biotransformations of icariin (1) by cell suspension cultures of Glycyrrhiza uralensis and Morus alba yielded two new metabolites, icaruralins A and B (2 and 3), and one known metabolite, baohuoside I (4). Their structures were determined on the basis of extensive spectroscopic analysis. This is the first report that the cell suspension cultures of G. uralensis and M. alba possess deglycosylation functionality.
Characterization of a novel thermostable glucose-tolerant GH1 β-glucosidase from the hyperthermophile Ignisphaera aggregans and its application in the efficient production of baohuoside I from icariin and total epimedium flavonoids
Jiang, Jianchun,Wei, Min,Xie, Jingcong,Xu, Hao,Yang, Jing,Zhang, Ning,Zhao, Jian
, (2020)
The minor flavonoid baohuoside I from Herba epimedii has better bioactivities than its precursor compounds icariin and other major epimedium flavonoids. In this study, a novel β-glucosidase gene (Igag_0940) was cloned and expressed to improve the conversion efficiency in the process of baohuoside I production. For the first time, the recombinant IagBgl1 was purified and then identified uniquely as a trimer in GH 1 family protein from Archaea. The maximum activity of recombinant IagBgl1 was exhibited at 95 °C, pH 6.5, and it retained more than 70% after incubation at 90 °C for 4 h. IagBgl1 had a high catalytic activity towards icariin with a Kcat/Km ratio of 488.19 mM?1·s?1. Under optimized conditions (65 °C, pH 6.5, 0.8 U/mL enzyme, and 90 min), 10 g/L icariin was transformed into 7.564 g/L baohuoside I with a molar conversion of 99.48%. Meanwhile, 2.434 g/L baohuoside I was obtained from 10 g/L total epimedium flavonoids by a two-step conversion system built with IagBgl1 and two other thermostable enzymes. This is the first report of enzymatic conversion for producing baohuoside I by thermostable enzymes.
Baohuoside i production through enzyme hydrolysis and parameter optimization by using response surface and subset selection
Yang, Qianxu,Wang, Li,Zhang, Liangxiao,Xiao, Hongbin
, p. 132 - 138 (2013)
A rapid and efficient baohuoside I preparation method was established. A uniform design coupled with subset selection was employed to determine pH, reaction time, and temperature parameters, as well as dextranase hydrolysis efficiency. Hydrolysis parameters were optimized using response surface and subset selection. Our results showed that pH plays an important role in the hydrolysis reaction within a relatively narrow range (pH 4-7). Temperature was the secondary factor, which was positively correlated with conversion rate. A 3-h reaction time was sufficient. Finally, a relatively good hydrolysis parameters were found, and their effectiveness was verified.
Biotransformation of major flavonoid glycosides in herb epimedii by the fungus Cunninghamella blakesleana
Xin, XiuLan,Fan, Guang-Jun,Sun, Zheng,Zhang, Ning,Li, Ye,Lan, Rong,Chen, Liang,Dong, PeiPei
, p. 141 - 146 (2015)
Biotransformation of icariin (1), epimedin C (2), epimedoside A (3), epimedin A (4) and epimidin B (5), five major components of E. koreanum, were performed by using Cunninghamella blakesleana. And they could be metabolized efficiently to icariside II (1a), 2″-O-rhamnosylikarisoside II (2a), epimedoside b (3a), baohuoside VII (4a) and sagittatoside B (5a) with high yields of 95.1%, 97.7%, 93.7%, 95.8% and 96.4%, respectively. And these transformed products as major forms of herb epimedii in vivo exhibited the more significant anti-osteoporosis activities. Our method could be applied for enriching these rare flavonoids in herb epimedii, for further development of anti-osteoporosis medicines or functional foods.
ANALOGS OF THE NATURAL PRODUCT ICARIIN
-
Paragraph 00168; 00182, (2020/03/02)
Provided herein are analogs of the natural product icariin represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The analogs can be used to modulate (e.g., inhibit, such as by competitive inhibition) PDE5 and thereby treat a wide range of PDE5- mediated diseases, including cardiovascular, gastrointestinal, pulmonary, musculoskeletal, neurological and reproductive diseases. Also provided herein are compositions and methods including compounds of Structural Formula (I).